Using e-Technologies to Maximize Physical Activity After Cancer Treatment

Using e-Technologies to Maximize Physical Activity After Cancer Treatment: The eMPACT Trial

The Cancer Exercise app (CEA) is designed to promote physical activity among cancer survivors. The proposed randomized controlled clinical trial will investigate, in adults who have completed cancer treatment, the effects of a 12-week home-based exercise program, delivered using CEA, on physical activity levels. Participants will be randomized into one of two groups: (1) CEA or (2) Usual Care.

Study Overview

• Status: Not yet recruiting
• Conditions: Cancer
• Intervention / Treatment: Behavioral: Cancer Exercise App

• Study Type: Interventional
• Enrollment (Estimated): 750
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Research Coordinator; Phone Number: (352) 294-1742; Email: eMPACT@hhp.ufl.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18 to 85 years of age
• Diagnosed with stage I-III cancer
• Completed all primary cancer treatments (e.g., surgery, radiation, chemotherapy) at least 6 months prior to enrollment. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, immunotherapy, and bisphosphonates are allowed within 6 months of study enrolment and during study participation.
• Own a smartphone with data plan or access to WiFi (Apple or Android)
• Medical clearance provided or no medical clearance needed based on exercise preparticipation screening.

Exclusion Criteria:

• consistently engage in >300 min/week of moderate-intensity physical activity or 150 min/week of vigorous-intensity physical activity in the past 3 months
• receiving or scheduled to receive surgery or radiation during study participation
• have stage IV metastatic cancer or evidence of cancer recurrence
• have multiple myeloma
• have received bone marrow or hematopoietic stem cell transplant within past year
• are unable to walk without support or have severe weakness or balance problems that limit safe participation in exercise
• contraindications to participate in unsupervised exercise
• are pregnant
• unable to read, speak and understand English

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cancer Exercise app group	Behavioral: Cancer Exercise App; Use of Cancer Exercise app to increase physical activity levels among cancer survivors.
No Intervention: Usual Care group; Participants assigned to Usual Care group will receive no intervention. After completing the post-intervention assessments, they will be provided with information on how to download and use the Cancer exercise app.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in moderate to vigorous physical activity from pre- to post-intervention	Moderate to vigorous physical activity will be assessed using the International Physical Activity Questionnaire, a well-validated and reproducible questionnaire for use among cancer survivors	Baseline and following the 12-week intervention

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: University of Florida Health Cancer Institute
• Investigators: Principal Investigator: Demetra Christou, PhD, University of Florida; Principal Investigator: Danielle Jake-Schoffman, PhD, University of Florida

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2026
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2028

Study Registration Dates

• First Submitted: April 10, 2026
• First Submitted That Met QC Criteria: April 10, 2026
• First Posted (Actual): April 17, 2026

Study Record Updates

• Last Update Posted (Actual): April 22, 2026
• Last Update Submitted That Met QC Criteria: April 16, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: IRB202501619

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No